 |
May 19, 2011 Medgenics to Present at the 10th Annual IISI Biomed 2011 Conference |
 |
Nov. 22, 2010 Extension of Agreement on Factor VIII Biopump |
|
Nov. 08, 2010 Award of US Government QTDP Grant |
|
Oct. 19, 2010 Chairman of the Board to take active executive role to help increase US Activities |
|
Oct. 27, 2010 Successful closing of $4m Convertible Debenture Issue |
|
Sept. 23, 2010 Medgenics CEO to Present at Rodman and Renshaw Annual Global Investment Conference |
|
Sept. 2, 2010 Dr. Stephen Ettinger, Joins SAB |
|
Sept. 1, 2010 Notice of Annual Meeting on September 13, 2010 |
|
Aug. 24, 2010 Proposed New Convertible Debenture Issue |
|
Aug. 23, 2010 Alastair Clemow, PhD Joins Board of Directors |
|
Jul 19, 2010: Medgenics Announces New Results in Phase I/II Trials to Treat Anaemia |
|
Jun 22, 2010: Higher Dose EPO Biopumps Working in Patients |
|
Jun 09, 2010: Medgenics Enhances Strategic Advisory Board |
|
May 26, 2010: Medgenics Successfully Closes Additional Financing Round |
|
May 17, 2010: Appointment of Nomura-Code as Joint-Broker |
|
Apr 27, 2010: Medgenics Granted Approval for Extension of Anaemia Trial to Major New Medical Centre |
|
Apr 15, 2010: Sustained INTERFERON ALFA-2b (IFNα) Production IN VITRO and Delivery IN VIVO by Medgenics dermal Microrgan Biopumps showcased at the Major European Liver meeting in Vienna |
|
Mar 30, 2010: Medgenics Presents First Data on Interferon Producing Biopumps at the 2010 EASL Conference in Vienna |
|
Oct 23, 2009: Medgenics Signs development agreement with major international pharma company |
|
Sep 3 2009: CEO to Present at Rodman & Renshaw Conference |
|
Aug 27 2009: Patient Nearing Unprecedented 11 months of Anemia Relief |
|
June 11 2009: Medgenics CEO to Present EPODURE AT Biomed Conference |
|
May 22 2009: Preliminary Results: The Annual Report and Accounts of the Company |
|
May 11 2009: Medgenics requests Stockholder Action in connection with fund raising through the proposed issue of convertible debentures |
|
Mar 27 2009: Encouraging results of the Company’s ongoing EPODURE Biopump Phase I/II Clinical Trial |
|
Feb 27 2009: Crystal Research Issues Quarterly Update |
|
Feb 3 2009: Medgenics Announces Positive Data from Phase I/II Clinical
Trial of Epodure Treatment of Anemia in Chronic Kidney Disease |
|
Nov 3 2008: Medgenics Announces Preliminary Data: The landmark Phase I/II clinical trial of Medgenics’ EPODURE Biopump, for providing sustained |
|
July 30, 2008: Medgenics Granted Approval: to Commence Its Landmark Phase I/II Clinical Study of EPODURE to treat Anemia |
|
April 14, 2008: Research Update: Medgenics on target to start Phase I/II clinical trials with EPODURE protein therapy for anaemia mid-2008 as planned
|
|
Mar 18, 2008: Medgenics consolidates corporate and R&D
operations into new office facility
|
|
Feb 1, 2008: Lord Steinberg Appointment, Medgenics (AIM: MEDG), the US incorporated biopharmaceutical company that was admitted to AIM in December 2007, is pleased to announce...
|
|
Dec 4, 2007: ADMISSION TO TRADING Karmiel, Israel and London, UK – 4 December, 2007 – Medgenics (AIM: MEDG), the US incorporated holding company of a biopharmaceutical group, is pleased to announce...
|
|
Nov 29, 2007: Medgenics raises £3.28 Million in initial public offering in conjunction with forthcoming listing on AIM Karmiel, Israel and London, UK - 29 November, 2007 - Medgenics, Inc., a US biopharmaceutical company with key operations in Israel...
|
| |
Nov 5-7, 2007: Rodman Renshaw Annual Healthcare Conference |
|
Nov 1, 2006: Medgenics To Present At Rodman & Renshaw 8th Annual Healthcare Conference
CEO to Share Clinical Proof of Principle and Development Strategy
|
